表皮葡萄球菌喹诺酮耐药临床分离株中DNA回旋酶的GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.
作者信息
Li Z, Deguchi T, Yasuda M, Kawamura T, Kanematsu E, Nishino Y, Ishihara S, Kawada Y
机构信息
Department of Urology, Gifu University School of Medicine, Gifu, Japan.
出版信息
Antimicrob Agents Chemother. 1998 Dec;42(12):3293-5. doi: 10.1128/AAC.42.12.3293.
Abstract
We examined 22 clinical isolates of Staphylococcus epidermidis to analyze the association of alterations in GyrA and ParC with fluoroquinolone resistance. The simultaneous presence of GyrA and ParC alterations was associated with a high level of fluoroquinolone resistance in the clinical isolates of S. epidermidis.
摘要
我们检测了22株表皮葡萄球菌临床分离株，以分析GyrA和ParC改变与氟喹诺酮耐药性之间的关联。GyrA和ParC改变同时存在与表皮葡萄球菌临床分离株的高水平氟喹诺酮耐药性相关。
相似文献
1
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.表皮葡萄球菌喹诺酮耐药临床分离株中DNA回旋酶的GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1998 Dec;42(12):3293-5. doi: 10.1128/AAC.42.12.3293.
2
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.粪肠球菌中与喹诺酮耐药性相关的DNA回旋酶GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1998 Feb;42(2):433-5. doi: 10.1128/AAC.42.2.433.
3
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.体外筛选携带DNA促旋酶和拓扑异构酶IV改变的耐氟喹诺酮淋病奈瑟菌。
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
4
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.肺炎克雷伯菌喹诺酮耐药临床分离株中DNA促旋酶的GyrA亚基和拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1997 Mar;41(3):699-701. doi: 10.1128/AAC.41.3.699.
5
Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.新型氟喹诺酮类药物DU-6859a对DNA旋转酶GyrA亚基和拓扑异构酶IV的ParC亚基发生基因改变的耐喹诺酮淋病奈瑟菌临床分离株的抗菌活性。
J Antimicrob Chemother. 1997 Feb;39(2):247-9. doi: 10.1093/jac/39.2.247.
6
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.耐喹诺酮淋病奈瑟菌：DNA 回旋酶 GyrA 亚基和拓扑异构酶 IV 的 ParC 亚基改变与抗菌药物敏感性谱的相关性
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
7
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.阴沟肠杆菌喹诺酮耐药临床分离株中gyrA和parC基因突变的检测
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
8
Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC.空肠弯曲菌中喹诺酮类高水平耐药性的快速出现与gyrA和parC的突变变化有关。
Antimicrob Agents Chemother. 1998 Dec;42(12):3276-8. doi: 10.1128/AAC.42.12.3276.
9
Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii.弗氏柠檬酸杆菌临床分离株中与氟喹诺酮耐药性相关的gyrA和parC基因突变。
FEMS Microbiol Lett. 1997 Sep 15;154(2):409-14. doi: 10.1111/j.1574-6968.1997.tb12675.x.
10
Serotyping of quinolone-resistant Neisseria gonorrhoeae isolates with alterations in GyrA and ParC.对具有GyrA和ParC改变的耐喹诺酮淋病奈瑟菌分离株进行血清分型。
J Antimicrob Chemother. 1998 Mar;41(3):418-20. doi: 10.1093/jac/41.3.418.
引用本文的文献
1
Species Distribution, Antimicrobial Resistance, and Enterotoxin Profiles of Non- Staphylococci Isolated from Poultry Slaughterhouses in Korea.从韩国家禽屠宰场分离出的非葡萄球菌的物种分布、抗菌药物耐药性和肠毒素谱
Food Sci Anim Resour. 2025 May;45(3):744-758. doi: 10.5851/kosfa.2024.e58. Epub 2025 May 1.
2
Role of the Water-Metal Ion Bridge in Quinolone Interactions with Gyrase.水-金属离子桥在喹诺酮类药物与拓扑异构酶Ⅱ相互作用中的作用。
Int J Mol Sci. 2023 Feb 2;24(3):2879. doi: 10.3390/ijms24032879.
3
Experimental and Molecular Docking Studies of Cyclic Diphenyl Phosphonates as DNA Gyrase Inhibitors for Fluoroquinolone-Resistant Pathogens.环状二苯基膦酸酯作为耐氟喹诺酮病原体的DNA促旋酶抑制剂的实验和分子对接研究
Antibiotics (Basel). 2022 Jan 1;11(1):53. doi: 10.3390/antibiotics11010053.
4
Fluoroquinolone resistance of Staphylococcus epidermidis isolated from healthy conjunctiva and analysis of their mutations in quinolone-resistance determining region.表皮葡萄球菌从健康结膜分离氟喹诺酮耐药性及喹诺酮耐药决定区突变分析。
Antimicrob Resist Infect Control. 2020 Nov 4;9(1):177. doi: 10.1186/s13756-020-00841-3.
5
Oocytes can efficiently repair DNA double-strand breaks to restore genetic integrity and protect offspring health.卵母细胞可以有效地修复 DNA 双链断裂，以恢复遗传完整性并保护后代健康。
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11513-11522. doi: 10.1073/pnas.2001124117. Epub 2020 May 7.
6
Prevalence and Genetic Basis of Antimicrobial Resistance in Non- Staphylococci Isolated from Canadian Dairy Herds.从加拿大奶牛群中分离出的非葡萄球菌的抗菌药物耐药性流行情况及遗传基础
Front Microbiol. 2018 Feb 16;9:256. doi: 10.3389/fmicb.2018.00256. eCollection 2018.
7
Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance.喹诺酮类药物与炭疽芽孢杆菌gyrase的相互作用及耐药性基础
Biochemistry. 2017 Aug 15;56(32):4191-4200. doi: 10.1021/acs.biochem.7b00203. Epub 2017 Aug 1.
8
The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.喹诺酮类药物的现状：合成方法与抗菌活性
Molecules. 2016 Mar 28;21(4):268. doi: 10.3390/molecules21040268.
9
Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.氟喹诺酮与结核分枝杆菌gyrase的相互作用：增强对野生型和耐药gyrase的药物活性。
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E839-46. doi: 10.1073/pnas.1525055113. Epub 2016 Jan 20.
10
Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.喹诺酮CP-115,955对细菌和人类II型拓扑异构酶的活性是由不同的相互作用介导的。
Biochemistry. 2015 Feb 10;54(5):1278-86. doi: 10.1021/bi501073v. Epub 2015 Jan 23.
本文引用的文献
1
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.粪肠球菌中与喹诺酮耐药性相关的DNA回旋酶GyrA亚基和DNA拓扑异构酶IV的ParC亚基的改变。
Antimicrob Agents Chemother. 1998 Feb;42(2):433-5. doi: 10.1128/AAC.42.2.433.
2
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.金黄色葡萄球菌拓扑异构酶IV和DNA促旋酶的突变：对喹诺酮和香豆素活性的新型多效性影响。
Antimicrob Agents Chemother. 1998 Jan;42(1):121-8. doi: 10.1128/AAC.42.1.121.
3
DNA gyrase, topoisomerase IV, and the 4-quinolones.DNA 回旋酶、拓扑异构酶IV与4-喹诺酮类药物。
Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61.3.377-392.1997.
4
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用：喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
5
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.拓扑异构酶IV和DNA促旋酶作为环丙沙星在肺炎链球菌中的作用靶点。
Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321.
6
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.拓扑异构酶IV中的喹诺酮耐药性突变：与flqA位点的关系以及金黄色葡萄球菌中拓扑异构酶IV是氟喹诺酮类药物的主要靶点而DNA回旋酶是次要靶点的遗传学证据。
Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8. doi: 10.1128/AAC.40.8.1881.
7
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析：在氟喹诺酮耐药性中的作用
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
8
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.负责金黄色葡萄球菌喹诺酮耐药性的DNA拓扑异构酶IV grlA基因的改变。
Antimicrob Agents Chemother. 1996 May;40(5):1157-63. doi: 10.1128/AAC.40.5.1157.
9
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构：氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
10
DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.淋病奈瑟菌喹诺酮耐药临床分离株中的DNA回旋酶突变
Antimicrob Agents Chemother. 1995 Feb;39(2):561-3. doi: 10.1128/AAC.39.2.561.
Zotero 插件